BioInformant

Your Global Leader in Stem Cell Market Research

Home » Coronavirus (COVID-19) » Page 3

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

By

Promising results point to a potential alternative in combating the pandemic

San Diego, July 28, 2020 — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce the outcome of a COVID-19 patient treated using stem cells. Led by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR received approval for the treatment under the U.S. Food and Drug Administration (FDA) “expanded access for compassionate use” program. As of July 14, 2020, there have been more than 13 million COVID-19 cases and over 500,000 deaths worldwide. [Read more…]

Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update

By

MELBOURNE, Australia, May 08, 2020 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated guidance on its wider clinical development pipeline. [Read more…]

Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R)

By

GOLDEN, CO  July 14, 2020 — Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®. [Read more…]

Cellenkos’ Cord Blood T-Regulatory Cells Show Promise in COVID-19 Induced ARDS

By

HOUSTON, July 6, 2020 — Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), published in peer reviewed journal of Annals of Internal Medicine. Both patients were critically ill and intubated (one on ECMO). Both had failed Tociluzimab (Actemra, Roche) and had multiorgan failure. Patients received cell therapy under FDA Emergency Use IND for up to 3 doses. [Read more…]

How COVID-19 Is Impacting the Regenerative Medicine Sector

By

Today, we are facing a crisis that is unlike anything most of us have seen in our lifetimes. COVID-19 has brought health systems across the world to the fringe and forcefully closed schools, restaurants, events, and many other places around the world where we gather. The pandemic has killed countless lives and caused havoc in the lives of millions of workers. The ramifications of the pandemic are social and economic and will likely be felt for some time to come. [Read more…]

BioInformant's World-Class Clients